https://orcid.org/0000-0002-6905-4141
References
- Cavagna L, Nuño L, Scirè CA, et al. AENEAS (American and European Network of Antisynthetase Syndrome) collaborative group. Serum Jo-1 autoantibody and isolated arthritis in the antisynthetase syndrome: review of the literature and report of the experience of AENEAS collaborative group. Clin Rev Allerg Immunol. 2017;52:71–7.
- Satoh M, Tanaka S, Ceribelli A, et al. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allerg Immunol. 2017 Feb;52(1):1–19.
- Marie I, Josse S, Hatron PY, et al. Interstitial lung Disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Res Ther. 2013 May;65(5):800–808.
- Marie I, Josse S, Decaux O, et al. Comparison of long-term outcome between anti-Jo-1 and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev. 2012;11:739–745.
- Dobloug C, Garen T, Bitter H, et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis. 2015;74:1551–1556.
- Smoyer-Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculosketal Disord. 2012 Jun;15(13):103.
- Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology (Oxford). 2017 Jun 1;56(6):999–1007.
- Poveda Gomez F, Merino JL, Maté I, et al. Polymyositis associated with anti-Jo1 antibodies: severe cardiac involvement as initial manifestation. Am J Med. 1993;94:110–111.
- Frost NA, Morand EF, Hall CL, et al. Idiopathic polymyositis complicated by arthritis and mesangial proliferative glomerulonephritis: case report and review of the literature. Br J Rheumatol. 1993;32:929–931.
- Marguerie C, Bunn CC, Beynon HL, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J med. 1990;77:1019–1038.
- Zamora AC, Hoskote SS, Abascal-Bolade B, et al. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. Respir Med. 2016 Sep;118:39–45.
- Bauhammer J, Blank N, Max R, et al. Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response. J Rheumatol. 2016 Aug;43(8):1566–1574.
- Cavagna L, Nuño L, Scirè CA, et al. AENEAS (American, European Network of Antisynthetase Syndrome) collaborative group. Clinical spectrum time course in anti-Jo-1 positive antisynthetase syndrome. Results from an international retrospective multicenter study. Med August. 2015;94(32):1–7.
- Mileti LM, Strek ME, Niewold TB, et al. Clinical characteristics of patients with anti–jo-1 antibodies: a single center experience. J Clin Rheumotolol. 2009;15(5):254–255.
- Hyldgaard C, Hilberg O, Muller A, et al. A cohort study of interstitial lung diseases in central Denmark. Respir Med. 2014;May:108(5):793–799.
- Passadore I, Ladarola P, Di Poto C, et al. 2-DE and LC-MS/MS for a comparative proteomic analysis of BALf from subjects with different subsets of inflammatory myopathies. J Proteome Res. 2009 May;8(5):2331–2340.
- Cavagna L, Carapoli R, Abdi-Ali L, et al. Cyclosporine in anti-Jo1- positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol. 2013;49(4):483–492.
- Schnabel A, Reuter M, Biederer J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum. 2003;32(5):273–284.
- Sem M, Molberg O, Lund MB, et al. Rituximab treatment of the anti synthetase syndrome – a retrospective case series. Rheumatology. 2009;48:968–971.
- Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease. The relevance of histopathologic and radiographic pattern. Chest Nov. 2009;136(5):1397–1405.
- Saunders P, Tsipouri V, Keir GJ, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017 jun 15;18(1):275.